Zealand Pharma A/S (ZLDPF) Stock Price, News & Analysis

Company Overview

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia. The company is also developing glepaglutide, a long‐acting GLP-2 analog for the management of short bowel syndrome, with ongoing clinical trials assessing its ability to reduce parenteral support dependency. Zealand has entered strategic collaborations with leading pharmaceutical firms to co‐develop and commercialize select programs, leveraging global regulatory and commercial expertise to accelerate patient access.

Founded in 1998 and headquartered in Copenhagen, Zealand Pharma conducts research and development activities in Scandinavia while maintaining partnerships and licensing agreements that extend its reach to markets in Europe, North America and Asia. The company’s leadership, including CEO Emmanuel Dulac, brings together expertise in peptide science, clinical development and corporate strategy. Zealand Pharma’s dual listing on the Copenhagen Stock Exchange and OTC markets in the U.S. underscores its commitment to broad investor engagement and global growth.

Key Stats

• Today's Range: $42.89 to $42.89
• 50-Day Range: $38.95 to $54.32
• 52-Week Range: $35.93 to $83.12
• Volume: 110 shs
• Average Volume: 1,691 shs
• Market Capitalization: $3.07 billion
• P/E Ratio: 3.18
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Moderate Buy

Zealand Pharma A/S Stock Analysis - MarketRank™

Zealand Pharma A/S scored higher than 36% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Zealand Pharma A/S has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 strong buy ratings, no buy ratings, 7 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Zealand Pharma A/S has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: -12.24%

Earnings Growth

Earnings for Zealand Pharma A/S are expected to decrease by -12.24% in the coming year, from $2.37 to $2.08 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Zealand Pharma A/S is 3.18, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 45.97.

Price to Earnings Ratio vs. Sector

The P/E ratio of Zealand Pharma A/S is 3.18, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.13.

Price to Book Value per Share Ratio

Zealand Pharma A/S has a P/B Ratio of 1.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.52% of the float of Zealand Pharma A/S has been sold short.

Short Interest Ratio / Days to Cover

Zealand Pharma A/S has a short interest ratio ("days to cover") of 76.04, which indicates bearish sentiment.

Change versus previous month

Short interest in Zealand Pharma A/S has recently decreased by 63.84%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Zealand Pharma A/S does not currently pay a dividend.

Dividend Growth

Zealand Pharma A/S does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.53

News Sentiment

Zealand Pharma A/S has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Zealand Pharma A/S this week, compared to 1 article on an average week.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Zealand Pharma A/S insiders have not sold or bought any company stock.

Percentage Held by Institutions

Zealand Pharma A/S has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 6/28/2026
• Next Earnings (Estimated): 8/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:ZLDPF
• Previous Symbol: NASDAQ:ZLDPF
• CIK: 2068427
• Web: www.zealandpharma.com
• Phone: 45-8877-3600
• Fax: 45-8877-3898
• Employees: 340
• Year Founded: 1998

Profitability

• EPS (Trailing Twelve Months): $13.48
• Trailing P/E Ratio: 3.18
• Forward P/E Ratio: 18.10
• P/E Growth: N/A
• Net Income: $977.29 million
• Net Margins: 68.82%
• Pretax Margin: 74.39%
• Return on Equity: 41.80%
• Return on Assets: 38.49%

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 37.17
• Quick Ratio: 37.17

Sales & Book Value

• Annual Sales: $1.40 billion
• Price / Sales: 2.20
• Cash Flow: $13.84 per share
• Price / Cash Flow: 3.10
• Book Value: $31.61 per share
• Price / Book: 1.36

Miscellaneous

• Outstanding Shares: 71,530,000
• Free Float: N/A
• Market Cap: $3.07 billion
• Optionable: Not Optionable
• Beta: 0.86